Biosimilar infliximab for Behcet's syndrome: a case series

Dincses E., Esatoglu S. N., Ozguler Y., Uygunoglu U., Hamuryudan V., Seyahi E., ...Daha Fazla

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.37, sa.6, ss.111-115, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 6
  • Basım Tarihi: 2019
  • Dergi Adı: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.111-115
  • Anahtar Kelimeler: Behcet's syndrome, bio-similar, infliximab, DISEASE, RECOMMENDATIONS, MULTICENTER, EFFICACY
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Objective. The efficacy and safety of biosimilar infliximab (bio-IFX) was shown in randomised controlled trials and it was approved for all indications of the reference product in several countries. However, a previous case series of 3 patients with Behcet's syndrome (BS) reported disappointing results. We aimed to share our experience with bio-IFX treatment in different types of organ involvement in patients with BS.